In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies

By Ruth Beran
Friday, 24 June, 2005

The sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed. A 90-day convertible note has been issued by Advance to Pharmanet, satisfying the $400,000 settlement payment.

David Kenley, VP corporate development and one of the founders of Metabolic Pharmaceuticals (ASX:MBP), has resigned from the company to become CEO of Xceed Biotechnology (ASX:XBL). Kenley will leave Metabolic on 1 July and join Xceed in mid July.

Henry Bosch has been appointed as a non-executive director of Genetic Technologies (ASX:GTG).

Content from other channels on our network

Siemens expands Queensland manufacturing facility

Customer demand exceeding capacity for Alpha HPA

Curtin University project to research sustainable gallium processing

How to extend the life of your motor bearings

Mars Petcare Wodonga expansion boosts manufacturing output

Unify risk and compliance to protect patients.

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available

From raw to rare sugar: low-cal sweetener under development

Upcycling cauliflower waste into protein ingredients for future food

Keeping pace with changing appetites

Maize miller reaps the benefit of gravity metal detectors

The potential of AI technologies across the food supply chain

In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network